Podcast
Hear the podcastG. Steven Burrill
Welcome from the CEO
Flash required to view this video. Download the latest version here
G. Steven BurrillNews
Biotech posts gain in February as broader markets strengthen March 03, 2010 | Press Release
Biotech holds steady in January as broader markets head south February 01, 2010 | Press Release
Biotech Closes the Year on an Upswing January 04, 2010 | Press Release
See all News
Ann F. Hanham
Managing DirectorPrior to joining Burrill & Company, Ann Hanham was a co-founder and Vice President of Clinical & Regulatory Affairs at InterMune Pharmaceuticals, and prior to that, the Senior Director for Oncology Product Development at Otsuka Pharmaceuticals and the Medical Director for Celtrix Pharmaceuticals. She has also worked for Becton Dickinson in both regulatory and clinical affairs for the monoclonal antibody program, and as a regulatory toxicologist with the Health Protection Branch of Health and Welfare Canada.
Dr. Hanham holds a Ph.D. from the University of British Columbia, an MSc from Simon Fraser University, and a BSc from the University of Toronto. She was also Board Certified in Toxicology in 1986.
She currently is a member of the Board of Directors of Adlyfe, Aerovance, BioTie, Endocyte, Logical Therapeutics, SCYNEXIS, Taiwan Liposome, and Waterstone.



